Salivary cytokine profiles in primary Sjögren's syndrome differ from those in non-sjögren sicca in terms of TNF-α levels and Th-1/Th-2 ratios

Clinical and Experimental Rheumatology

Volumn 29, Issue 6, 2011, Pages 970-976

  Kang, Eun Ha ^a   Lee, Yun Jong ^a,b   Hyon, Joon Young ^c   Yun, Pil Young ^a   Song, Yeong Wook ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Cytokine; Saliva; Sicca; Sj gren's syndrome

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; SALIVA LEVEL; SALIVATION; SJOEGREN SYNDROME; TH1 CELL; TH17 CELL; TH2 CELL;

CYTOKINES; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-4; KERATOCONJUNCTIVITIS SICCA; MALE; MIDDLE AGED; SALIVA; SALIVARY GLANDS; SECRETORY RATE; SJOGREN'S SYNDROME; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863296483     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. BAYETTO K, LOGAN RM: Sjögren's syndrome: a review of aetiology, pathogenesis, diagnosis and management. Aust Dent J 2010;55(Suppl. 1):39-47.
2. FOX RI, RANG HI, ANDO D, ABRAMS J, PISA E: Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. J Immunol 1994;152:5532-9. (Pubitemid 24153003)
3. BOUMBAD, SKOPOULI FN, MOUTSOPOULOS HM: Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren's syndrome. Br J Rheumatol 1995;34:326-33.
4. OHYAMA Y, NAKAMURA S, MATSUZAKI G et al.: Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 1996;39:1376-84. (Pubitemid 26270098)
5. MCARTHUR C, WANG Y, VENO P, ZHANG J, FIORELLA R: Intracellular trafficking and surface expression of SS-A (Ro), SS-B (La), poly (ADP-ribose) polymerase and alphafodrin autoantigens during apoptosis in human salivary gland cells induced by tumour necrosis factor-alpha. Arch Oral Biol 2002;47:443-8. (Pubitemid 34760754)
6. KULKARNI K, SELESNIEMI K, BROWN TL: Interferon-gamma sensitizes the human salivary gland cell line, HSG, to tumor necrosis factor-alpha induced activation of dual apoptotic pathways. Apoptosis 2006;11:2205-15. (Pubitemid 44885396)
7. BRAYER JB, CHA S, NAGASHIMA H et al.: IL-4-dependent effector phase in autoimmune exocrinopathy as defined by the NOD. IL-4-gene knockout mouse model of Sjögren's syndrome. Scand J Immunol 2001;54:133-40. (Pubitemid 32592338)
8. CHA S, BRAYER J, GAO J et al.: A dual role for interferon-gamma in the pathogenesis of Sjögren's syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand J Immunol 2004;60:552-65. (Pubitemid 39665100)
9. LEE BH, TUDARES MA, NGUYEN CQ: Sjögren's syndrome: an old tale with a new twist. Arch Immunol Ther Exp (Warsz) 2009;57:57-66.
10. NGUYEN CQ, HU MH, LI Y, STEWART C, PECK AB: Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in humans and mice. Arthritis Rheum 2008;58:734-43. (Pubitemid 351364871)
11. SAKAI A, SUGAWARA Y, KUROISHI T, SASANO T, SUGAWARA S: Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 2008;181:2898-906.
12. CAULI A, YANNI G, PITZALIS C, CHALLA-COMBE S, PANAYI GS: Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjögren's syndrome and chronic sialoadenitis. Ann Rheum Dis 1995;54:209-15.
13. AJJAN RA, MCINTOSH RS, WATERMAN EA et al.: Analysis of the T-cell receptor Valpha repertoire and cytokine gene expression in Sjögren's syndrome. Br J Rheumatol 1998;37:179-85.
14. VAN WOERKOM JM, KRUIZE AA, WENTING-VAN WIJK MJ et al.: Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjögren's syndrome compared with non-Sjögren's sicca syndrome. Ann Rheum Dis 2005;64:1474-9. (Pubitemid 41623860)
15. ZHU L, SHEN J, ZHANG C et al.: Inflammatory cytokine expression on the ocular surface in the Botulium toxin B induced murine dry eye model. Mol Vis 2009;15:250-8.
16. VITALI C, BOMBARDIERI S, JONSSON R et al.: Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8. (Pubitemid 34539104)
17. LEE YJ, SCOFIELD RH, HYON JY et al.: Salivary chemokine levels in patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2010;49:1747-52.
18. WORLD HEALTH ORGANIZATION: Oral health survey: basic methods. 3rd edition. Geneva, 1987.
19. GREENSPAN JS, DANIELS TE, TALAL N, SYL-VESTER RA: The histopathology of Sjögren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 1974;37:217-29.
20. FIETTA P, DELSANTE G, QUAINI F: Hematologic manifestations of connective autoimmune diseases. Clin Exp Rheumatol 2009;27:140-54.
21. MITSIAS DI, TZIOUFAS AG, VEIOPOULOU C et al.: The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjögren's syndrome. Clin Exp Immunol 2002;128:562-8. (Pubitemid 34639321)
22. REKSTEN TR, JONSSON MV, SZYSZKO EA, BRUN JG, JONSSON R, BROKSTAD KA: Cytokine and autoantibody profiling related to histopathological features in primary Sjögren's syndrome. Rheumatology (Oxford) 2009;48:1102-6.
23. DE VITA S, DOLCETTI R, FERRACCIOLI G et al.: Local cytokine expression in the progression toward B cell malignancy in Sjögren's syndrome. J Rheumatol 1995;22:1674-80.
24. JONSSON MV, DELALEU N, BROKSTAD KA, BERGGREEN E, SKARSTEIN K: Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland. Arthritis Rheum 2006;54:2300-5. (Pubitemid 44051088)
25. GAO J, KILLEDAR S, CORNELIUS JG, NGUYEN C, CHA S, PECK AB: Sjögren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotypespecific autoimmune disease. J Autoimmun 2006;26:90-103. (Pubitemid 43138879)
26. NGUYEN CQ, GAO JH, KIM H, SABAN DR, CORNELIUS JG, PECK AB: IL-4-STAT6 signal transduction-dependent induction of the clinical phase of Sjögren's syndromelike disease of the nonobese diabetic mouse. J Immunol 2007;179:382-90. (Pubitemid 46986555)
27. BIKKER A, VAN WOERKOM JM, KRUIZE AA et al.: Increased expression of interleukin-7 in labial salivary glands of patients with primary Sjögren's syndrome correlates with increased inflammation. Arthritis Rheum 2010;62:969-77.
28. KAMACHI M, KAWAKAMI A, YAMASAKI S et al.: Regulation of apoptotic cell death by cytokines in a human salivary gland cell line: distinct and synergistic mechanisms in apoptosis induced by tumor necrosis factor alpha and interferon gamma. J Lab Clin Med 2002;139:13-9. (Pubitemid 34197033)
29. MCARTHUR C, WANG Y, VENO P, ZHANG J, FIORELLA R: Intracellular trafficking and surface expression of SS-A (Ro), SS-B (La), poly (ADP-ribose) polymerase and alphafodrin autoantigens during apoptosis in human salivary gland cells induced by tumour necrosis factor-alpha. Arch Oral Biol 2002;47:443-8. (Pubitemid 34760754)
30. SISTO M, LISI S, LOFRUMENTO DD et al.: Induction of TNF-alpha-converting enzymeectodomain shedding by pathogenic autoantibodies. Int Immunol 2009;21:1341-9.
31. LISI S, SISTO M, LOFRUMENTO DD et al.: Pro-inflammatory role of anti-Ro/SSA autoantibodies through the activation of Furin-TACE-amphiregulin axis. J Autoimmun 2010;35:160-70.
32. ZANDBELT MM, DE WILDE P, VAN DAMME P, HOYNG CB, VAN de PUTTE L, VAN den HOOG-EN F: Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. J Rheumatol 2004;31:96-101. (Pubitemid 38067529)
33. MAVRAGANI CP, NIEWOLD TB, MOUTSOPO-ULOS NM, PILLEMER SR, WAHL SM, CROW MK: Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum 2007;56:3995-4004. (Pubitemid 350262327)
34. MOUTSOPOULOS NM, KATSIFIS GE, ANGEL-OV N et al.: Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis 2008;67:1437-43.
35. EWERT P, AGUILERA S, ALLIENDE C et al.: Disruption of tight junction structure in salivary glands from Sjögren's syndrome patients is linked to proinflammatory cytokine exposure. Arthritis Rheum 2010;62:1280-9.
36. BAKER OJ, CAMDEN JM, REDMAN RS et al.: Proinflammatory cytokines tumor necrosis factor-alpha and interferon-gamma alter tight junction structure and function in the rat parotid gland Par-CIO cell line. Am J Physiol Cell Physiol 2008;295:C1191-201. (Pubitemid 352790331)
37. JORKJEND L, JOHANSSON A, JOHANSSON AK, BERGENHOLTZ A: Periodontitis, caries and salivary factors in Sjögren's syndrome patients compared to sex-and age-matched controls. Oral Rehabil 2003;30:369-78. (Pubitemid 37356785)
38. KURU B, MCCULLOUGH MJ, YILMAZ S, PORTER SR: Clinical and microbiological studies of periodontal disease in Sjögren syndrome patients. J Clin Periodontal 2002;29:92-102. (Pubitemid 41697741)